Tafamidis is SFDA-registered at an 80-90% tender discount to US list, but fewer than 8 GCC centres offer the Tc-PYP scintigraphy needed to diagnose ATTR-CM, gating the opportunity on diagnostics, not drug access.
Tafamidis (Vyndaqel/Vyndamax, Pfizer), which produced a 29.5% relative reduction in all-cause mortality in ATTR-ACT, is SFDA-registered (2021) and MOH UAE-registered (2022), available via specialist prescription at cardiology centres including KAMC, KFSH&RC, and AUH. Annual tafamidis tender pricing in KSA runs approximately SAR 70,000-90,000, versus a US WAC equivalent near SAR 850,000 — an 80-90% discount reflecting GCC reference pricing to Portugal and Greece plus direct negotiating leverage. NPHC evaluation of tafamidis for ATTR-CM has not yet been formalised in KSA; access today runs on specialist prescription with case-by-case MOH approval. Vutrisiran (Amvuttra, Alnylam) for ATTR-PN carries a GCC registration timeline of 18 to 24 months behind its 2022 FDA approval, is registered in some GCC states, and sees limited uptake given underdeveloped polyneuropathy diagnosis pathways and the specialist neurology expertise it requires.
The primary barrier to the GCC ATTR opportunity is diagnostic infrastructure, not drug registration or price. Tc-PYP scintigraphy, the non-invasive diagnostic standard for ATTR-CM, is available at fewer than 8 centres across all six GCC states (KAMC, KFSH&RC, AUH, HMC Doha, OCCI Muscat), and most HFpEF patients in the region are managed by general cardiologists without ATTR screening, leaving an estimated diagnosis rate below 5% of true prevalence. The GCC also carries its own genetic profile: hereditary ATTR (ATTRv) variants beyond the globally common Val30Met include several Arabian Peninsula-specific mutations (Ala97Ser, Glu89Gln) documented in Saudi, UAE, and Omani kindreds, with total ATTRv burden estimated at 500 to 1,000 patients regionwide — while wild-type ATTR in the ageing cardiac population remains severely underdiagnosed given the scintigraphy access gap.
Transthyretin amyloidosis agents in the GCC — registration and access status, 2026
| Drug (Brand / INN) | Mechanism | Company | GCC Registration | Key Trial Result | GCC Access Status |
|---|---|---|---|---|---|
| Vyndaqel / Vyndamax (tafamidis) | Oral TTR stabiliser | Pfizer | SFDA registered 2021; MOH UAE 2022 | ATTR-ACT — mortality reduction 29.5% | NPHC evaluation ongoing; available via specialist prescription; cardiology centres KAMC/KFSH&RC/AUH; ~80-90% tender discount to US list |
| Amvuttra (vutrisiran) | siRNA — SC, ATTR-PN | Alnylam | GCC registration timeline 18–24 months post-FDA (approved 2022 FDA) | HELIOS-A — ATTR-PN indication | Registered in some GCC states; limited uptake; neurology-centre expertise required |
Sources: GCC Cardiology Society ATTR working group 2023; Al-Tayeb A et al. Amyloid 2020; GCC hereditary ATTR registry (KFSH&RC); Saudi MOH tender database 2023; Pfizer GCC pricing disclosures.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Saudi MOH tender pricing benchmark and reference-country methodology
- NPHC evaluation status and case-by-case approval pathway for ATTR-CM
- Cardiology-centre prescriber map (KAMC, KFSH&RC, AUH)
- Vutrisiran registration timeline vs tafamidis precedent
Delivers
- Tc-PYP-capable centre mapping across the six GCC states
- HFpEF referral pathway analysis and general-cardiology screening gap
- Diagnosis-rate modelling vs true prevalence estimates
- Recommendations for diagnostic-infrastructure investment or partnership
Delivers
- Arabian Peninsula ATTRv variant documentation (Saudi/UAE/Omani kindreds)
- ATTRv vs ATTRwt prevalence split and screening implications
- KFSH&RC hereditary ATTR registry findings
- Genetic-testing access mapping for at-risk family screening
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why tafamidis dominates ATTR-CM via specialist prescription at KAMC, KFSH&RC, and AUH, while vutrisiran's ATTR-PN uptake lags behind underdeveloped polyneuropathy diagnosis pathways
- How NPHC evaluation of tafamidis for ATTR-CM remains unformalised in KSA, leaving access to run on case-by-case MOH approval
- Tafamidis's 29.5% relative reduction in all-cause mortality in ATTR-ACT against vutrisiran's HELIOS-A ATTR-PN indication and 18-24 month GCC registration lag
- Why vutrisiran sees limited GCC uptake despite registration in some states, given the specialist neurology expertise its diagnosis pathway requires
- Why Tc-PYP scintigraphy, the non-invasive ATTR-CM diagnostic standard, is available at fewer than 8 centres across all six GCC states
- How most HFpEF patients are managed by general cardiologists without ATTR screening, leaving an estimated diagnosis rate below 5% of true prevalence
- Arabian Peninsula-specific ATTRv mutations (Ala97Ser, Glu89Gln) documented in Saudi, UAE, and Omani kindreds beyond the globally common Val30Met variant
- An estimated 500-1,000 regional ATTRv patients, and why wild-type ATTR in the ageing cardiac population remains severely underdiagnosed given the scintigraphy gap
- Tafamidis's SFDA registration (2021) and MOH UAE registration (2022) against an 80-90% tender-price discount to the US WAC-equivalent list price
- Why NPHC evaluation of tafamidis for ATTR-CM has not yet been formalised, and what that implies for vutrisiran's registration precedent
- How KAMC, KFSH&RC, and AUH anchor the GCC cardiology KOL network prescribing tafamidis for ATTR-CM
- Why HFpEF referral patterns from general cardiology, not specialist capacity, are the binding constraint on expanding the treated population
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (SFDA registration data, MOH tender documentation), peer-reviewed literature, and GCC-specific registry data — not secondary summaries. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
GCC ATTR Amyloidosis CI sources: the GCC Cardiology Society ATTR working group 2023 report, Al-Tayeb A et al. (Amyloid 2020), the KFSH&RC hereditary ATTR registry, the Saudi MOH tender database 2023, and Pfizer GCC pricing disclosures.
- Drug SFDA/MOH registration status and tender pricing verified against the Saudi MOH tender database 2023 and Pfizer GCC pricing disclosures
- Tc-PYP diagnostic capacity and diagnosis-rate estimates verified against the GCC Cardiology Society ATTR working group 2023 report
- GCC-specific ATTRv genetic variants verified against Al-Tayeb A et al., Amyloid 2020, and the KFSH&RC hereditary ATTR registry
- ATTRv vs ATTRwt burden estimates verified against the KFSH&RC hereditary ATTR registry
Frequently asked questions
Commission this brief
AXLRx delivers GCC ATTR amyloidosis competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams entering the Gulf. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.